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Background: A phase II clinical trial previously evaluated the sequential administration of erlotinib after
chemotherapy for advanced non-small-cell lung cancer (NSCLC). This current pilot study assessed the feasibility of
sequential induction therapy in patients with stage IIB to IIIA NSCLC adenocarcinoma.
Methods: Patients received gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 75 mg/m2 on day 1, followed
by oral icotinib (125 mg, three times a day) on days 15 to 28. A repeatcomputed tomography(CT) scan evaluated
the response to the induction treatment after two 4-week cycles and eligible patients underwent surgical resection.
The primary objective was to assess the objective response rate (ORR), while EGFR and KRAS mutations and mRNA
and protein expression levels of ERCC1 and RRM1 were analyzed in tumor tissues and blood samples.
Results: Eleven patients, most with stage IIIA disease, completed preoperative treatment. Five patients achieved
partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ORR=45%) and six
patients underwent resection. Common toxicities included neutropenia, alanine transaminase (ALT) elevation,
fatigue, dry skin, rash, nausea, alopecia and anorexia. No serious complications were recorded perioperatively. Three
patients had exon 19 deletions and those with EGFR mutations were more likely to achieve a clinical response
(P= 0.083). Furthermore, most cases who achieved a clinical response had low levels of ERCC1 expression and high
levels of RRM1.
Conclusions: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment
is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the
further investigation of these chemotherapeutic and molecularly targeted therapies.
Keywords: Non-small-cell lung cancer, Sequential, Induction chemotherapy, EGFR mutation, AdenocarcinomaBackground
Stage IIB to IIIA non-small-cell lung cancer (NSCLC)
has an unfavorable prognosis, with a low 5-year survival
rate that ranges from 19% to 25% using clinical stage
prediction, and a high recurrence rate despite aggressive
surgical management [1,2]. Numerous trials have investi-
gated the use of perioperative chemotherapy as a strategy
to improve survival. A pooled analysis by the Lung* Correspondence: zlyangyue@bjmu.edu.cn
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reproduction in any medium, provided the orAdjuvant Cisplatin Evaluation (LACE) Collaborative
Group presented a 5-year absolute benefit of 5.4% using
postoperative cisplatin-based chemotherapy, especially for
stage II to III cases of NSCLC (hazard ratio (HR) = 0.83)
[3]; while for the induction therapy, the Chemotherapy in
Early Stages Trial (ChEST) yielded a significant improve-
ment in terms of both disease-free survival (DFS; HR =
0.51) and overall survival (OS; HR = 0.42) of patients with
clinical stage IIB to IIIA NSCLC using preoperative
gemcitabine plus cisplatin [4].
Over the last decade, the development of targeted
therapies have held great promise for the treatment of
advanced NSCLC, and mutations of the epidermalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crucial factor that correlated with clinical responsiveness
to tyrosine-kinase inhibitors (TKI) [5,6]. Gefitinib and
erlotinib, which target the EGFR pathway, have been
accepted as a superior initial treatment to chemotherapy
for patients with EGFR mutations and advanced disease
[7,8]. Icotinib, which is a potent and selective EGFR-TKI,
provides a similar efficacy to gefitinib but with better toler-
ability for patients with NSCLC previously treated with
one or two chemotherapy agents [9,10].
Although four randomized phase III trials that evaluated
the efficacy of concurrent erlotinib or gefitinib administra-
tion with standard platinum-doublet chemotherapy failed
to show evidence of improved survival [11-14], the phase
II First-Line Asian Sequential Tarceva and Chemotherapy
Trial (FAST-ACT) proved that the sequential administra-
tion of TKI following chemotherapy led to a significant im-
provement in progression-free survival (PFS; P= 0.0002)
and patients showed a trend toward a better tumor re-
sponse rate (35.5% versus 24.4%;P = 0.12) [15].
Based on the above findings, we designed and conducted
this pilot study to assess the efficacy and tolerability of se-
quential gemcitabine/cisplatin and icotinib administration
as an induction therapy for patients with stage IIB to IIIA
NSCLC adenocarcinoma.
Methods
Study design and eligibility criteria
This was a single-arm study conducted in one center.
The primary objective was to assess the objective
response rate (ORR), while secondary objectives in-
cluded safety and perioperative complications, as well as
molecular markers for the prediction of tumor response.
Patients with histologically confirmed NSCLC adenocar-
cinoma at stage IIB or IIIA were eligible for enrollment
in this study. Other criteria included:age between >18
and <75 years old, an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 1, and ad-
equate hematological, hepatic and renal function
(hemoglobin >10 g/dL, neutrophil count >2.0 × 109/L,
platelet count >100 × 109/L, aspartate transaminase
(AST; also known as serum glutamic oxaloacetic trans-
aminase) <2.5 × the upper limit of normaland serum
creatinine <1.25 × the upper limit of normal). Magnetic
resonance imaging (MRI) studies of the brain, ultrasound
examinations of the abdomen and supraclavicular lymph
nodes, and bone scans were performed to exclude distant
metastases. Positron emission tomography-computed tom-
ography (PET-CT) was used as an option for staging.
Cardiac and pulmonary function tests were also required
before surgery was performed. Patients were excluded if
they had received prior chemotherapy, radiotherapy or
targeted therapy for any type of malignancy, and patients
with interstitial lung disease were also excluded. Informedconsent was obtained from patients who participated in
the study and the study protocol was approved by the insti-
tutional ethics board.Study treatment protocol
The chemotherapy regimen consisted of gemcitabine 1,250
mg/m2 on days 1 and 8, followed by cisplatin 75 mg/m2 on
day 1. Subsequently, patients received continuous oral dos-
ing with icotinib (125 mg, three times a day) on days 15 to
28 to complete the 4-week cycle. Toxicity was graded by
the National Cancer Institute Common Toxicity Criteria,
version 3.0. At the end of two cycles, a repeat computed
tomography(CT) was performed to evaluate the response
to the induction treatment according to the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria.
Subsequently, the resectability of each case was carefully
assessed by experienced thoracic surgeons, and eligible
patients proceeded directly to surgical resection within 2
weeks of the CT assessment. Perioperative complications
were also recorded.Tumor tissue and plasma samples
Tumor samples from pre-treatment biopsies and surgical
specimens were fixed in buffered formalin and embedded
in paraffin (FFPE) blocks. Sections from FFPE specimens
were stained with hematoxylin and eosin, and the pres-
ence of tumor cells was confirmed by a pathologist. Blood
samples were collected from each patient before and after
the induction treatment, and DNA was extracted from
plasma for further analysis.Detection of EGFR and KRAS mutations
Genomic DNA was extracted from the FFPE samples
using the QIAamp DNA FFPE Tissue Kit (Qiagen,
Hilden, Germany). The DNA concentrations were mea-
sured by a NanoDrop spectrophotometer (Thermo
Scientific, Waltham, MA, USA). The 30 hotspot muta-
tions within exons 18 to 21 of the EGFR gene were
examined using the Human EGFR Mutation Qualitative
Detection Kit (Beijing ACCB Biotech Ltd, Beijing,
China). Hydrolysable fluorescent probes were specific-
ally designed to detect different mutations (point muta-
tions, insertions and deletions). The seven hotspot
mutations in KRAS within codons 12 and 13 were
detected by the Human KRAS Mutation Qualitative
Detection Kit (Beijing ACCB Biotech Ltd, Beijing,
China). This experiment was performed using the
MX3000P PCR system (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s protocol. The PCR
conditions were as follows: initial denaturation at 95°C
for 10 minutes, followed by 40 cycles at 95°C for 15
seconds and 60°C for 1 minute.
Table 1 Patient characteristics before treatment
Variable Median (range) or frequency (%)


















CT, computed tomography; EBUS-TBNA, endobronchial ultrasound-guided
transbronchial needle aspiration; NSCLC, non-small-cell lung cancer.
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(DHPLC) analysis
As described previously [16], EGFR (exon 19 and 21)
mutations were detected in plasma using DHPLC
Transgenomic Wave Nucleic Acid Fragment Analysis
System (Transgenomic, Omaha, NE, USA).
Quantitative real-time PCR
Total RNA samples from the FFPE tissue sections were
isolated by an RNeasy FFPE Kit (Qiagen) according to
the manufacturer’s instructions. The concentrations of
total RNAs were evaluated on the microspectrophotom-
eter (OD260/230 ≥1.7; OD260/280 = 2.0 ± 0.2). The
RNA samples were diluted to the working concentration
of 20 ng/μLto 200 ng/μL. The expression levels of
ERCC1 and RRM1 were examined using the Human
ERCC1 and RRM1 Expression Relative Quantitative
Detection Kits (Beijing ACCB Biotech Ltd). The reverse
transcription was performed at 25°C for 10 minutes,
followed by 37°C for 60 minutes. TaqMan probes were
used to detect the expression levels of ERCC1 and
RRM1. ACTB (encoding β-actin) was used as the in-
ternal control. The PCR amplification was performed on
the MX3000P (Stratagene) and the procedures were as
follows: initial denaturation at 95°C for 10 minutes,
followed by 40 cycles at 95°C for 15 seconds and 60°C
for 1 minute. The relative amount of target genes was
normalized to the internal reference gene (ACTB) using
the 2-ΔCt method (ΔCt = Cttarget gene-CtACTB). The rela-
tive expression level of ERCC1 and RRM1 was then cate-
gorized as high, moderate or low.
Immunohistochemistry
Briefly, 4-μm paraffin sections from paraffin blocks of
clinical samples were prepared. After deparaffinization,
the sections were treated with hydrogen peroxide
(H2O2) for 5 minutes to block the endogenous peroxid-
ase. These sections were stained with the mouse mono-
clonal anti-ERCC1 antibody (ZM-0138; ZSGB Biotech
Ltd, Beijing, China) and anti-RRM1 antibody (60073-1-1
g; Proteintech Group, Chicago, IL, USA). The tumor
was considered to show positive expression when more
than 10% of tumor cells were stained at any intensity.
Statistical analysis
The primary end point was the ORR according to the
RECIST criteria. On the basis of a 45% response rate
with a 95% confidence interval (CI) equal to the
response rate plus or minus 30%, a sample size of 11 pa-
tients was estimated as necessary. The objective of statis-
tical analysis was to detect the degree of correlation
between the radiographic response to the induction
treatment and the presence of an EGFR mutation. Statis-
tical analysis was performed using patched SPSS 17.0 forWindows software (SPSS Inc, Chicago, IL, USA). Data
were tested using Fisher’s exact test and the analysis
results were considered significant at a level of P< 0.05.
Results
Patient characteristics
A total of 11 patients were enrolled in this study be-
tween August 2011 and April 2012 at a single depart-
ment of Peking University Cancer Hospital (Beijing,
China). The clinical characteristics of the patients are
listed in Table 1. The patients included five males and
six females, and most patients were identified as having
stage IIIA disease before treatment; three patients had a
bulky N2 metastasis. The majority of patients were diag-
nosed with adenocarcinoma (10 out of 11 patients),
while one patient was diagnosed with adenosquamous
carcinoma postoperatively.
Treatment delivered and toxicity
All 11 patients enrolled in the study completed two cy-
cles of sequential treatment and six patients went on to
undergo surgical resection. The median time from the
start of treatment to surgery was 71 days, and the me-
dian time from the last dose to surgery was 14 days. The
toxicities that occurred during the induction therapy are
listed in Table 2. Most of the adverse events were grade
1 or 2, while only one case of grade 3 neutropenia was
recorded. Common toxicities included neutropenia,
Table 2 Toxicities related to the study treatment
Toxicity Grade Total
1 2 3 4
Hematological
Leukopenia 3 2 0 0 5/11 (45%)
Neutropenia 2 2 1 0 5/11 (45%)
Anemia 2 0 0 0 2/11 (18%)
Thrombocytopenia 2 1 0 0 3/11 (27%)
Biochemical
Increased ALT 6 0 0 0 6/11 (55%)
Non-hematological
Rash 4 3 0 0 7/11 (64%)
Dry skin 4 2 0 0 6/11 (55%)
Pruritus 3 0 0 0 3/11 (27%)
Alopecia 6 2 0 0 8/11 (73%)
Mucositis 2 0 0 0 2/11 (18%)
Fatigue 5 2 0 0 7/11 (64%)
Anorexia 7 0 0 0 7/11 (64%)
Pyrexia 0 0 0 0 0/11 (0%)
Weight loss 0 0 0 0 0/11 (0%)
Nausea 9 0 0 0 9/11 (82%)
Vomiting 2 1 0 0 3/11 (27%)
Diarrhea 2 0 0 0 2/11 (18%)
Constipation 5 0 0 0 5/11 (45%)
ALT, alanine transaminase.
Lv et al. World Journal of Surgical Oncology 2013, 11:96 Page 4 of 7
http://www.wjso.com/content/11/1/96alanine transaminase (ALT) elevation, fatigue, dry skin,
rash, nausea, alopecia and anorexia. Neither dose reduc-
tion nor discontinuation was required in the induction
cycles.
Treatment efficacy and surgical outcomes
After two cycles of sequential administration, 5 out of 11
patients achieved a partial response (PR) according to
the RECIST criteria resulting in a response rate of 45%,
but no complete response (CR) was observed. Among
the six other patients, five patients had stable disease
(SD) and one patient had progressive disease (PD) owing
to the appearance of a supraclavicular lymph node me-
tastasis. After the induction therapy was evaluated, all
five patients with PR and the one patient with SD under-
went surgery; while another three patients with SD and
bulky mediastinal lymph node metastases received
pemetrexed for chemotherapy owing to the unresectability
of their disease. One patient with SD refused to undergo
resection and opted for radiotherapy. The patients with
PD also received radiotherapy.
For the six patients who received surgery, five patients
underwent a complete lobectomy combined with system-
atic mediastinal lymph node dissection, and the otherpatient underwent a thoracotomy and exploration; pleural
dissemination (M1a) was found and the operation was
halted. Among the five lobectomies, two patients had a
bronchoplasty and no angioplasty was performed. The
postoperative pathological examinations confirmed that
the diagnosis was consistent with the pre-treatment biopsy
in all cases except one adenosquamous carcinoma, and no
pathologic complete response (pCR) was noted. Two cases
were down-staged by means of induction therapy, and an-
other two patients who had been previously diagnosed
stage IIB were later diagnosed to be mediastinal lymph
node metastasis (stage IIIA). Postoperative complications
included one case each of atelectasis, supraventricular
arrhythmia and wound infection. No intraoperative
hemorrhage or postoperative death was observed.
Molecular marker analyses
EGFR mutation analysis was performed on biopsy sam-
ples of nine patients before induction therapy, two of
whom had exon 19 deletions. After surgery, specimens
from six patients were available for analysis and three
patients were confirmed to harbor exon 19 deletions.
Neither exon 18, 20, 21, nor KRAS mutations, were
detected in this cohort of patients. An increased trend
toward achieving a clinical response was noted in pa-
tients with EGFR mutations, although the difference was
not statistically significant (P= 0.083). Plasma samples of
11 patients were collected before treatment in addition
to the six surgical samples after induction therapy. How-
ever, no EGFR mutations were detected in the plasma
samples collected according to the DHPLC method.
Expression analysis was only performed in resected tu-
mors, and we observed that five out of six patients had
high mRNA levels of RRM1 and low levels of ERCC1.
All of these patients were scored as ERCC1-negative and
three patients were RRM1-positive according to immu-
nohistochemistry, respectively. All of the molecular data
and treatment outcomes are listed in Table 3.
Discussion
To our knowledge, this is the first study to use sequential
treatment as an induction therapy for NSCLC, and ORR
was our primary outcome measure. The CHEST study
achieved a response rate of 35.4% with gemcitabine and
cisplatin as the induction regimen. Three clinical trials
have evaluated the efficacy of preoperative EGFR-TKI, all
of which enrolled patients with stage I to II NSCLC. The
ORRs of these studies were unstable, ranging from 0% to
42% [17-19]. In our study, we observed a response rate of
45% in patients with stage IIB to IIIA NSCLC, which was
comparable to previous studies of induction therapy use
for patients with early stage disease and for advanced
disease in the FAST-ACT trial (ORR = 35.5%). In addition,
the sequential administration of icotinib and chemotherapy
Table 3 Treatment outcomes for patients associated with molecular marker status
Patient Gender Smoking
status
EGFR status ERCC1 RRM1 CR
Biopsy SS Pre-Pl Post-Pl mRNA IHC mRNA IHC
1 M Current Wild Ex19 Del Wild Wild + (−) +++ (+) PR
2 F Never Wild / Wild / / / / / SD
3 F Never Wild / Wild / / / / / SD
4 M Current / Wild Wild Wild + (−) +++ (−) SD
5 F Never Wild Wild Wild Wild + (−) +++ (−) PR
6 F Never Wild Wild Wild Wild + (−) +++ (+) PR
7 F Never Wild / Wild / / / / / SD
8 F Never Ex19 Del Ex19 Del Wild Wild + (−) +++ (+) PR
9 M Current Wild / Wild / / / / / PD
10 M Current Ex19 Del Ex19 Del Wild Wild ++ (−) ++ (−) PR
11 M Former / / Wild / / / / / SD
CR, clinical response; EGFR, epidermal growth factor receptor; F, female; IHC, immunohistochemistry; M, male; PD, progressive disease; post-Pl: post-treatment
plasma; PR, partial response; pre-Pl: pre-treatment plasma; SD, stable disease; SS, surgical specimen.
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perioperatively. This was a better result than that of previ-
ous studies, especially with regards to rash and diarrhea.
This result was consistent with the ICOGEN trial, which
showed that icotinib caused less toxicity than gefitinib,
although the number of cases in this study is too limited to
make definite conclusions in this regard [10].
It is unclear whether the targeted therapy or chemo-
therapy plays the most important role in achieving clin-
ical response in each patient. However, an EGFR
mutation is one of the most important factors to be con-
sidered. In the FAST-ACT study, six samples were avail-
able for the EGFR mutation analysis from patients who
received sequential treatment, of which two patients had
exon 19 deletions and achieved a PR. Among 11 pa-
tients, we observed that all three cases with an exon 19
deletion had a clinical response after induction therapy;
for the seven patients with wild-type EGFR, only two
met the criteria for a response. This result was consist-
ent with previous studies regarding gefitinib induction
therapy [19]. Although only a non-significant trend was
observed in favor of patients harboring EGFR mutations
(P= 0.083), we believe that the difference would be
significant if more patients were enrolled and unselected
for other molecular markers.
It has been proven that RRM1 and ERCC1 mRNA
levels and protein expression are predictive of response
to gemcitabine and platinum-based chemotherapy
[20,21]. In our study, most of the patients who had
achieved a clinical response had low levels of ERCC1
mRNA and high levels of RRM1 mRNA, which was
similar to the postoperative immunohistochemistry re-
sults. One possible explanation is that RRM1 expression
status might not be the crucial factor in this sequential
treatment. In addition, although Bepler et al. concludedthat post-chemotherapy gene expression levels were rep-
resentative of pre-treatment levels, the analysis of 10
cases may not be sufficient. Furthermore, it has been
noted that gene expression levels increase after chemo-
therapy, which indicates that gemcitabine may alter
RRM1 mRNA levels [22]. To confirm this theory, a
further study is needed to assess patients, with a radio-
graphic response in particular.
Since EGFR mutation status has been considered to be
a predictor of response to EGFR-TKI, the identification
of patients with an EGFR mutation is important for the
use of sequential induction therapy. Tumor tissue is the
best choice for EGFR mutation analysis and these enable
the microdissection of tumor cells. In our study, the
postoperative samples of three patients were found to
have exon 19 deletions, one of which could not be
detected in the analysis of biopsy tissue preoperatively.
Intratumor heterogeneity for EGFR mutation has been
proven to exist by the analysis of different areas of a single
NSCLC tumor [23], and further evidence of this hetero-
geneity stems from the predictive benefit of EGFR-TKI
treatment from the relative abundance of EGFR muta-
tions [24]. However, the difference in treatment efficacy
between patients with and without heterogeneity ap-
pears to lie with PFS and OS, rather than the radio-
graphic response, and the patient in our study also
achieved a PR. When insufficient biopsy tissue or tumor
cells are available for mutation analysis, the detection of
mutations in plasma DNA might be an alternative. It
has been reported that approximately 80% of mutations
could be detected in both the plasma DNA and the cor-
responding tumor samples in patients with stage IIIB to
IV disease [16]. However, in our analysis, no EGFR mu-
tation was detected in any plasma samples, either pre-
or post-treatment. This negative result may have been
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rived from tumor tissues of patients with stage IIB to
IIIA and advanced-stage NSCLC.
Conclusion
Two cycles of sequentially administered gemcitabine/cis-
platin with icotinib as the induction treatment is a feas-
ible and efficacious approach for stage IIB to IIIA
NSCLC adenocarcinoma. This regimen showed a prom-
ising ORR with no observed additional toxicity or post-
operative complications, but this should be confirmed
by studies with larger sample sizes. EGFR mutations
appeared to be a predictor for response, which will be
confirmed by further studies that may identify other
molecular markers of clinical response as a result of
sequential therapy.
Consent
Written informed consent was obtained from the
patients for publication of this report and any accom-
panying images.
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